Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older
- You have stage IIIB, IIIC, or IV non-small cell lung cancer with PD-L1 levels between 1% and 49%
- Your cancer does not have certain gene changes (EGFR mutation or ALK translocation) that can be treated with pills
- You have not had chemotherapy or immunotherapy for cancer that has spread, though you could have had these treatments earlier for localized disease
- You are in generally stable health with adequate kidney, liver, and blood cell counts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.